Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Nov
10
Today In Oncology
FDA Approves Pimicotinib for Symptomatic TGCT
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo